Mario Sznol, MD Named Vice-Chief of Medical Oncology
For Immediate Release
Date: 4/14/05
Contact : Renee Gaudette (203) 785-2143
Yale Cancer Center is pleased to announce Dr. Mario Sznol as Vice-Chief of the Section of Medical Oncology. In this position, Dr. Sznol will play a key leadership role in helping to direct the academic and clinical research activities of the Section.
“Dr. Sznol has an international reputation as one of the leading experts in cancer drug development. He is uniquely qualified to serve in this important leadership position in the Section, and I look forward to working closely with him as we continue to focus on building state-of-the-art clinical programs and on providing the best cancer care to our patients,” said Dr. Edward Chu, Chief of Medical Oncology at Yale Cancer Center.
Dr. Sznol currently cares for patients with melanoma and serves as head of the melanoma disease unit. In addition, he fulfills a critical position at Yale Cancer Center as Chairman of the Protocol Review Committee and as a member of the Yale Human Investigations Committee.
Dr. Sznol’s expertise and experience is in cancer immunotherapy, drug development for cancer, and treatment of patients with melanoma and renal cell carcinoma. He is working to establish strong multidisciplinary clinical research program for patients with melanoma by expanding the opportunities for clinical trials at Yale Cancer Center, particularly those focusing on immunotherapy and novel agents.
Dr. Sznol is a graduate of Baylor College of Medicine in Houston and completed his fellowship training in medical oncology at the Mount Sinai School of Medicine in New York.
Formerly, Dr. Sznol was a Senior Investigator and Head of the Biologics Evaluation Section of the Investigational Drug Branch at the National Cancer Institute (NCI). While at the NCI, Dr. Sznol also attended on the clinical services of the Biological Response Modifiers Program and the Immunotherapy Service of the Surgery Branch. From 1999-2004, he was Vice President for Clinical Affairs at Vion Pharmaceuticals, a drug development company in New Haven, CT.
Yale Cancer Center is one of a select network of 39 comprehensive cancer centers in the country designated by the National Cancer Institute and the only one in Southern New England. The Center harnesses the scientific resources of Yale University School of Medicine, Yale-New Haven Hospital, and Yale University.